Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-03-13

Clinical Trial Update: A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) [Phase 3]

View source ↗

Summary

A Phase 3 trial named Panorama evaluating MM120 for generalized anxiety disorder is currently recruiting, sponsored by Definium Therapeutics US, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MM120

Snippet

Sponsor: Definium Therapeutics US, Inc. | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: RECRUITING